年龄相关性黄斑变性患者玻璃体内注射雷珠单抗治疗后的视网膜神经纤维层厚度变化。
Retinal nerve fiber layer thickness changes in patients with age-related macular degeneration treated with intravitreal ranibizumab.
机构信息
Servicio de Oftalmologia, Hospital Clinico San Carlos, Departamento de Oftalmologia, Facultad de Medicina, Universidad Complutense de Madrid, 28040 Madrid, Spain.
出版信息
Invest Ophthalmol Vis Sci. 2012 Sep 14;53(10):6214-8. doi: 10.1167/iovs.12-9875.
PURPOSE
To assess the effects of intravitreal ranibizumab therapy on intraocular pressure (IOP) and retinal nerve fiber (RNFL) thickness.
METHODS
Forty-nine eyes of 49 patients with neovascular age-related macular degeneration (AMD) treated with intravitreal ranibizumab injections and 27 fellow eyes not requiring treatment were followed for 1 year. RNFL thickness, as measured by Fourier domain optical coherence tomography, and IOP were determined pre- and postinjection.
RESULTS
After 12 months, the mean number of injections received was 4.8 ± 1.6. The incidence of IOP elevations (>5 mm Hg over baseline) observed at the time of injection was 0.4%. Baseline RNFL thickness was 105.7 ± 12.2 μm in the treatment group compared with 101.8 ± 11.6 μm in the control group (P = 0.176). At the end of follow-up, significant RNFL thinning was noted in the treatment group (100.2 ± 11.0 μm, P < 0.001), whereas no differences were found in the control group (100.5 ± 10.8 μm, P = 0.477).
CONCLUSIONS
Intravitreal ranibizumab injections used to treat AMD caused a significant change in RNFL thickness after 12 months of follow-up.
目的
评估玻璃体内雷珠单抗治疗对眼内压（IOP）和视网膜神经纤维（RNFL）厚度的影响。
方法
对 49 例年龄相关性黄斑变性（AMD）新生血管患者的 49 只眼进行玻璃体内雷珠单抗注射治疗，并对 27 只无需治疗的对侧眼进行了为期 1 年的随访。使用傅里叶域光学相干断层扫描（OCT）测量 RNFL 厚度和眼压（IOP），并在注射前后进行检测。
结果
12 个月后，平均注射次数为 4.8±1.6 次。注射时观察到的 IOP 升高（比基线升高>5mmHg）发生率为 0.4%。治疗组的基线 RNFL 厚度为 105.7±12.2μm，对照组为 101.8±11.6μm（P=0.176）。随访结束时，治疗组的 RNFL 明显变薄（100.2±11.0μm，P<0.001），而对照组无差异（100.5±10.8μm，P=0.477）。
结论
玻璃体内雷珠单抗注射治疗 AMD 可导致 12 个月随访后 RNFL 厚度发生显著变化。
Zotero 插件